Integra LifeSciences (NASDAQ:IART) Issues Q2 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its second quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.600-0.650 for the period, compared to the consensus estimate of 0.750. The company issued revenue guidance of $411.0 million-$416.0 million, compared to the consensus revenue estimate of $395.8 million. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.

Analyst Ratings Changes

Several research firms have commented on IART. Truist Financial dropped their price objective on shares of Integra LifeSciences from $37.00 to $25.00 and set a hold rating on the stock in a report on Tuesday. StockNews.com lowered shares of Integra LifeSciences from a buy rating to a hold rating in a research report on Tuesday, April 30th. Wells Fargo & Company cut shares of Integra LifeSciences from an overweight rating to an equal weight rating and dropped their price objective for the stock from $45.00 to $25.00 in a research note on Tuesday. Citigroup raised shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price objective for the company in a report on Wednesday, April 3rd. Finally, Oppenheimer cut shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $39.00.

Integra LifeSciences Stock Up 5.9 %

NASDAQ IART traded up $1.36 during mid-day trading on Tuesday, reaching $24.50. The stock had a trading volume of 1,020,126 shares, compared to its average volume of 772,755. The stock has a market cap of $1.93 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a fifty day moving average price of $33.33 and a 200 day moving average price of $38.33. Integra LifeSciences has a 1 year low of $22.36 and a 1 year high of $51.12. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. During the same quarter last year, the business posted $0.74 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. On average, research analysts expect that Integra LifeSciences will post 3.19 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.